March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
EMBER3 data in the context of other treatment options in ET-pretreated HR+/HER2- MBC
Dec 15, 2024, 08:38

EMBER3 data in the context of other treatment options in ET-pretreated HR+/HER2- MBC

Paolo Tarantino, Working towards a PhD in clinical research at the University of Milan, shared a post on LinkedIn:

Harold J. Burstein from Dana-Farber’s Breast Oncology Center puts the EMBER3 data in the context of other treatment options in ET-pretreated HR+/HER2- MBC.”

 EMBER3 data in the context of other treatment options in ET-pretreated HR+/HER2- MBC

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.